Sandoz Keeps Tabs On Teva Skinny Label Ruling
As Q3 Sales Reveal ‘Two Sides’ To Sandoz
As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.
